MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development

Spring House, Pa., May 5, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the Measurable residual disease Partnership and Alliance in Acute myeloid leukemia Clinical Treatment (MPAACT), an industry-led research alliance founded in 2018 between Janssen Research & Development, LLC, Genentech (a member of the Roche Group), Novartis, and Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, and recently expanded with additional members Amgen, AbbVie, and Kronos Bio, is advancing efforts to establish measurable residual disease (MRD) as a surrogate endpoint for overall survival in the treatment of acute myeloid leukemia (AML).AML is a difficult to treat blood cancer with significant unmet medical need as one of the most common types of leukemias in adults and a five-year relative survival of less than 30 percent.1 Clinical trials for new therapies in AML are becoming increasingly lengthy to complete based on the traditional clinical endpoint of survival. MRD is a measure of the number of cancer cells that remain after chemotherapy in patients and its presence is associated with survival.2,3 Undetectable MRD (uMRD), sometimes referred to as MRD-negativity, means that residual cancer cells were not detected using a specific and highly sensitive test. While it is frequently defined as less than one cancer cell in 10,000 leukocytes, the threshold may vary by cancer type. Formally establishing MRD/uMRD association with overall ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news